DK2715352T3 - Fremgangsmåde til vurdering af risiko for pml - Google Patents

Fremgangsmåde til vurdering af risiko for pml Download PDF

Info

Publication number
DK2715352T3
DK2715352T3 DK12792375.3T DK12792375T DK2715352T3 DK 2715352 T3 DK2715352 T3 DK 2715352T3 DK 12792375 T DK12792375 T DK 12792375T DK 2715352 T3 DK2715352 T3 DK 2715352T3
Authority
DK
Denmark
Prior art keywords
pml
assessing
risk
procedure
Prior art date
Application number
DK12792375.3T
Other languages
Danish (da)
English (en)
Inventor
Meena Subramanyam
Tatiana Plavina
Gary Lewis Bloomgren
Carmen Bozic
Sophia Lee
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47260338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2715352(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK2715352T3 publication Critical patent/DK2715352T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exhaust Gas After Treatment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK12792375.3T 2011-05-31 2012-05-31 Fremgangsmåde til vurdering af risiko for pml DK2715352T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161491810P 2011-05-31 2011-05-31
US201161508584P 2011-07-15 2011-07-15
US201161550257P 2011-10-21 2011-10-21
US201261636588P 2012-04-20 2012-04-20
PCT/US2012/040283 WO2012166971A2 (en) 2011-05-31 2012-05-31 Method of assessing risk of pml

Publications (1)

Publication Number Publication Date
DK2715352T3 true DK2715352T3 (da) 2019-05-20

Family

ID=47260338

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19169482.7T DK3575792T3 (da) 2011-05-31 2012-05-31 Fremgangsmåde til vurdering af risiko for pml
DK12792375.3T DK2715352T3 (da) 2011-05-31 2012-05-31 Fremgangsmåde til vurdering af risiko for pml

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19169482.7T DK3575792T3 (da) 2011-05-31 2012-05-31 Fremgangsmåde til vurdering af risiko for pml

Country Status (19)

Country Link
US (2) US20190227064A1 (pl)
EP (3) EP3575792B1 (pl)
JP (5) JP6243838B2 (pl)
KR (3) KR102292563B1 (pl)
CN (1) CN103635803A (pl)
AU (1) AU2012262122B2 (pl)
CA (1) CA2836490A1 (pl)
CY (1) CY1121981T1 (pl)
DK (2) DK3575792T3 (pl)
ES (2) ES2729945T3 (pl)
FI (1) FI3575792T3 (pl)
HR (2) HRP20230186T1 (pl)
HU (2) HUE043339T2 (pl)
LT (2) LT2715352T (pl)
PL (2) PL2715352T3 (pl)
PT (2) PT2715352T (pl)
RS (2) RS58967B1 (pl)
SI (2) SI3575792T1 (pl)
WO (1) WO2012166971A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641513C (en) 2006-02-28 2021-09-21 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
ES2666372T3 (es) 2009-10-11 2018-05-04 Biogen Ma Inc. Ensayos relacionados con anti-VLA-4
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
EP2524060B1 (en) 2010-01-11 2017-11-29 Biogen MA Inc. Assay for jc virus antibodies
ES2729945T3 (es) 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
US20160223565A1 (en) * 2013-09-18 2016-08-04 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
EP3110976B1 (en) * 2014-02-27 2020-05-13 Biogen MA Inc. Method of assessing risk of pml
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MX2020004238A (es) 2017-10-26 2020-10-05 Biogen Ma Inc Dosificación de natalizumab en intervalos prolongados.
WO2022104156A1 (en) 2020-11-14 2022-05-19 Biogen Ma Inc. Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
EP4323407A1 (en) 2021-04-13 2024-02-21 Biogen MA Inc. Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
EP1248112A3 (en) 1987-04-27 2004-08-25 Inverness Medical Switzerland GmbH Immunochromatographic specific binding assay device
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
WO1992012428A1 (en) 1991-01-11 1992-07-23 Quidel Corporation A one-step lateral flow nonbibulous assay
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
WO1993015217A1 (en) 1992-02-04 1993-08-05 Quidel Corporation Simplified extraction method for bacterial antigens using dried reagents
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
DE69329377T2 (de) 1992-03-10 2001-04-05 Quidel Corp., San Diego Trennmittel für rote blutkörperchen bei untersuchungen mit spezifischer bindung
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US6319676B1 (en) 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
EP1336850A1 (de) 1999-10-12 2003-08-20 Connex Gesellschaft zur Optimierung von Forschung und Entwicklung Verbessertes Verfahren zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
CN1400968A (zh) 2000-01-27 2003-03-05 美国氰胺公司 制备α－磺酰基异羟肟酸衍生物的方法
CA2405448A1 (en) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2004511807A (ja) 2000-10-17 2004-04-15 ベッスト−テスト　アンパーツゼルスカブ 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
CA2478547C (en) 2001-12-03 2011-09-20 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
TWI346558B (en) 2002-02-25 2011-08-11 Elan Pharm Inc Pharmaceutical composition for chronic treatment of inflammation and use thereof
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
AU2003243642A1 (en) 2002-06-21 2004-01-06 Mckesson Automation Inc. Closed loop medication use system and method
WO2005052567A1 (en) 2003-11-24 2005-06-09 Biogen Idec Ma Inc. Methods for detecting half-antibodies using chip-based gel electrophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
TWI418346B (zh) 2004-07-08 2013-12-11 Elan Pharm Inc 包括聚合物部分之多價ｖｌａ-４拮抗劑
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JP2008522971A (ja) 2004-12-03 2008-07-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症の発症の遅延または予防
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
LT3264094T (lt) 2005-04-04 2021-04-12 Biogen Ma Inc. Imuninio atsako į terapijos agentą įvertinimo būdai
AU2006269327A1 (en) * 2005-07-08 2011-11-10 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase A2
DK1940826T3 (da) 2005-09-29 2011-04-18 Elan Pharm Inc Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
NZ570679A (en) 2006-02-27 2011-01-28 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4
CA2641513C (en) 2006-02-28 2021-09-21 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP2009531304A (ja) 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
TW200846363A (en) 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
CN102272327B (zh) * 2008-11-07 2015-11-25 赛昆塔公司 通过序列分析监测状况的方法
CA2751364C (en) 2009-02-05 2017-06-20 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
WO2010096674A2 (en) 2009-02-20 2010-08-26 The Regents Of The University Of California A+ biomarker assays
EP2524060B1 (en) * 2010-01-11 2017-11-29 Biogen MA Inc. Assay for jc virus antibodies
ES2729945T3 (es) 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml

Also Published As

Publication number Publication date
JP2020101556A (ja) 2020-07-02
EP2715352B1 (en) 2019-04-24
KR102292563B1 (ko) 2021-08-24
EP4187248A1 (en) 2023-05-31
RS58967B1 (sr) 2019-08-30
CN103635803A (zh) 2014-03-12
EP3575792A1 (en) 2019-12-04
PT3575792T (pt) 2023-02-28
WO2012166971A3 (en) 2013-03-07
AU2012262122A1 (en) 2013-11-14
ES2939482T3 (es) 2023-04-24
HUE061244T2 (hu) 2023-06-28
SI3575792T1 (sl) 2023-04-28
EP2715352A2 (en) 2014-04-09
KR20190122878A (ko) 2019-10-30
HRP20230186T1 (hr) 2023-03-31
LT3575792T (lt) 2023-03-10
EP2715352A4 (en) 2015-10-21
HRP20190860T1 (hr) 2019-06-28
CA2836490A1 (en) 2012-12-06
US20190227064A1 (en) 2019-07-25
KR20210107138A (ko) 2021-08-31
AU2012262122B2 (en) 2016-12-08
CY1121981T1 (el) 2020-10-14
SI2715352T1 (sl) 2019-06-28
JP6243838B2 (ja) 2017-12-06
PT2715352T (pt) 2019-06-12
FI3575792T3 (fi) 2023-03-17
LT2715352T (lt) 2019-06-10
PL3575792T3 (pl) 2023-03-27
HUE043339T2 (hu) 2019-08-28
US20220011310A1 (en) 2022-01-13
PL2715352T3 (pl) 2019-09-30
KR102473834B1 (ko) 2022-12-02
KR20140038440A (ko) 2014-03-28
EP3575792B1 (en) 2022-11-30
KR102039751B1 (ko) 2019-11-01
JP2017191111A (ja) 2017-10-19
US12066442B2 (en) 2024-08-20
JP2022023126A (ja) 2022-02-07
JP2023169307A (ja) 2023-11-29
JP6663396B2 (ja) 2020-03-11
DK3575792T3 (da) 2023-02-27
RS63989B1 (sr) 2023-03-31
JP2014518377A (ja) 2014-07-28
ES2729945T3 (es) 2019-11-07
JP7128221B2 (ja) 2022-08-30
JP7353338B2 (ja) 2023-09-29
WO2012166971A8 (en) 2013-01-17
WO2012166971A2 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
DK2715352T3 (da) Fremgangsmåde til vurdering af risiko for pml
DK3829172T3 (da) Fremgangsmåde til at konstruere fletningsliste
DK2718404T3 (da) Fremgangsmåde til fremstilling af flydende carbonhydrider
DK3543333T3 (da) Fremgangsmåde til screening af alfa-amylaser
DK3225604T3 (da) Fremgangsmåde til fremstilling af flerlagsruder
DK2788767T3 (da) Fremgangsmåde til detektering af nukleosomaddukter
DK2595948T3 (da) Fremgangsmåde til fremstilling af ingenol-3-angelat
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
DK3275896T3 (da) Fremgangsmåde til at opnå antistoffer
FR2976634B1 (fr) Element de turbomachine
DK3985979T3 (da) Fremgangsmåde til bestemmelse af referenceenhed
DK2931188T3 (da) Støtte til forebyggelse af symptomer på femoro acetabulær indeklemning
FR2996411B1 (fr) Piege pour frelons
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2908724T3 (da) Fremgangsmåde til at følge udviklingen af en hjernelæsion
DK2834229T3 (da) Fremgangsmåde til fremstilling af ccr3-inhibitorer
DK2616101T3 (da) Fremgangsmåde til oprensning af pegyleret erythropoietin
DK2872536T3 (da) Fremgangsmåde til ekstraktion af biomasse
DK2916661T3 (da) Fremgangsmåde til opnåelse af bloom-hæmmende komponenter til konfektureprodukter
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK2582776T3 (da) Fremgangsmåde til opdræt af ascidier
DK2920151T3 (da) Fremgangsmåde til fremstilling af carboxamider
DK3002590T3 (da) En fremgangsmåde til at bestemme tilbøjeligheden til forkalkning
DK2704711T3 (da) Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
DK2558473T3 (da) Fremgangsmåde til fremstilling af dithiin-tetracarboximider